Study title: Leuproreline acetate in the treatment of central precocious puberty: a 12-month, multicenter, randomised, equivalence trial of two different depot formulations
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Endocrine System Diseases [C19] | |||||
Brands: Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: LEUPRORELIN | |||||
ATC code: | |||||
Document link: Leuprorelin_LEUb_CPP3M14_Synopsis.pdf | |||||
Document date: 2011-10-14 | |||||
Study number: LEUb/CPP3M/14/TIF | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | Y | - |